| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Share-based compensation | NaN | NaN | NaN | 389,114 |
| Other segment items | NaN | NaN | NaN | 396,481 |
| Professional fees | NaN | NaN | NaN | 543,168 |
| Operating expenses-CTIM76 | NaN | NaN | NaN | 1,445,862 |
| Operating expenses-CT95 | NaN | NaN | NaN | 1,488,530 |
| Operating expenses-CT202 | NaN | NaN | NaN | 3,149,238 |
| Research and development | 7,015,299 | 5,571,839* | 8,722,104 | NaN |
| Personnel-related costs | NaN | NaN | NaN | 2,345,969 |
| General and administrative | 2,328,500 | 2,181,251* | 1,888,376 | NaN |
| Loss from operations | -9,343,799 | -7,753,090* | -10,610,480 | -9,758,362 |
| Interest income | NaN | 667,229* | NaN | 903,772 |
| Other income (expense) | NaN | 119,231* | NaN | 27,080 |
| Net loss | NaN | -6,966,630 | NaN | -8,827,510 |
| Basic EPS | -0.09 | -0.073 | -0.1 | NaN |
| Diluted EPS | -0.09 | -0.073 | -0.1 | NaN |
| Basic Average Shares | 95,183,718 | 95,186,179 | 95,185,187 | NaN |
| Diluted Average Shares | 95,183,718 | 95,186,179 | 95,185,187 | NaN |
Context Therapeutics Inc. (CNTX)
Context Therapeutics Inc. (CNTX)